NasdaqGS:RAREBiotechs
A Look At Ultragenyx Pharmaceutical (RARE) Valuation After FDA Clears UX016 For GNE Myopathy
Ultragenyx Pharmaceutical (RARE) recently reported that the U.S. Food and Drug Administration cleared its Investigational New Drug application for UX016, a potential substrate replacement therapy for GNE myopathy, and a Phase 1/2 study is planned for 2026.
See our latest analysis for Ultragenyx Pharmaceutical.
Despite the UX016 milestone, the recent 30 day share price return of 17.49% decline and year to date share price return of 18.22% decline sit against a 1 year total shareholder return...


